Fundraising FoxAnaBios Corporation
San Diego, US · 3 known investors
Find your way into AnaBios Corporation
Sign up to see every warm intro you have to AnaBios Corporation
- Paths you didn't know you had: your email and LinkedIn already hold routes to the AnaBios Corporation team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
AnaBios generates predictive human data for pharmaceutical drug development, using authentic human cells and tissues from healthy and diseased donors to assess drug efficacy and toxicity before clinical trials. It offers human tissue procurement and functional assay services, including gene expression, proteomic, and metabolomic profiling, to support drug discovery and preclinical safety testing.
Founders & leadership
AG
Andre GhettiFounder · CEOAndre Ghetti holds a Ph.D. in Molecular and Cellular Physiology and completed postdoctoral studies in RNA biochemistry at Caltech. He is CEO and Chief Scientific Officer of AnaBios, where he develops ex-vivo platforms using human cells and tissues for preclinical drug discovery and safety assessment.
RF
Richard F. ErdmanNamed on SEC filing
PM
Paul MillerNamed on SEC filing
JR
Jack ReynoldsNamed on SEC filing
PC
Peter CrowleyNamed on SEC filing
GG
George GoldsmithNamed on SEC filing
MJ
Martin J. WatersNamed on SEC filing
Investors · 3
Reported raises · per SEC filings
Form D private placements$13.4M disclosed across 3 rounds · 2016–2022
▶$6.5MraisedJun 2022 · 1 investors · BiotechnologyRule 506(b)
▶$6.5MraisedJun 2022 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Melanie FanDirector
- Andre GhettiExecutive Officer
- Jack ReynoldsExecutive Officer, Director
- Peter CrowleyDirector
- Richard ErdmanDirector
- Paul E MillerExecutive Officer
- David AndersonDirector
- Offering amount
- $6.5M
- Amount sold
- $6.5M
- First sale
- May 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.1MraisedJun 2020 · 16 investors · BiotechnologyRule 506(b)
▶$1.1MraisedJun 2020 · 16 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Paul E MillerExecutive Officer
- George GoldsmithExecutive Officer
- Richard ErdmanDirector
- Peter CrowleyExecutive Officer, Director
- Jack ReynoldsExecutive Officer, Director
- Andre GhettiExecutive Officer
- Martin WatersExecutive Officer
- Offering amount
- $7M
- Amount sold
- $1.1M
- Sales commissions
- $490K
- Placement agents
- ARCADIA SECURITIES, LLC
- First sale
- Dec 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$5.8MraisedJun 2017 · 63 investors · BiotechnologyRule 506(b)
▶$5.8MraisedJun 2017 · 63 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Richard F. ErdmanDirector
- Paul MillerExecutive Officer
- Jack ReynoldsExecutive Officer, Director
- Peter CrowleyDirector
- George GoldsmithDirector
- Martin J. WatersExecutive Officer
- Andre GhettiExecutive Officer, Director
- Offering amount
- $8.4M
- Amount sold
- $5.8M
- Finders' fees
- $254.1K
- Placement agents
- CIM Securities, LLC, Brookline Group, LLC
- First sale
- May 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 2
OsmosisOsmosis is a US health education platform of short-form medical videos and learning tools, acquired by Elsevier.
LumenLumen Learning provides courseware and teaching tools built on open educational resources (OER) for higher education, aimed at faculty and students. Its products support course delivery, faculty professional development, and student-centered learning in colleges and universities.
Companies working in the same space as AnaBios Corporation.
Non-dilutive funding · 5 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2021 | $1.7M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2020 | $1.1M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2020 | $320.1K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2016 | $1.5M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2014 | $200.7K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does AnaBios Corporation do?
- AnaBios generates predictive human data for pharmaceutical drug development, using authentic human cells and tissues from healthy and diseased donors to assess drug efficacy and toxicity before clinical trials. It offers human tissue procurement and functional assay services, including gene expression, proteomic, and metabolomic profiling, to support drug discovery and preclinical safety testing.
- Who founded AnaBios Corporation?
- AnaBios Corporation was founded by Andre Ghetti.
- Who are AnaBios Corporation's investors?
- AnaBios Corporation's investors include Ampersand, Keiretsu Forum, Tech Coast Angels.
- How much funding has AnaBios Corporation raised?
- AnaBios Corporation has disclosed $13.4M raised across 3 rounds.
- Where is AnaBios Corporation headquartered?
- AnaBios Corporation is headquartered in San Diego, US.